[Optimization of the composition of the radioprotective complex APAETP+mexamine and analysis of its action]. 1986

V G Vladimirov, and I P Kamenko, and G A Poddubskiĭ, and S M Smirnova, and L G Tarnopol'skaia

The method of mathematical theory of experiment was used to find optimum variants of the radioprotective complex APAETP + mexamine. The character of their pharmacological interaction, depending on their dose ratio, was determined. It is suggested that it is conditioned by the specific role of different mechanisms involved in the radioprotective effect.

UI MeSH Term Description Entries
D008297 Male Males
D008735 5-Methoxytryptamine Serotonin derivative proposed as potentiator for hypnotics and sedatives. Meksamine,Methoxytryptamine,Mexamine,5 Methoxytryptamine
D009946 Organothiophosphorus Compounds Compounds containing carbon-phosphorus bonds in which the phosphorus component is also bonded to one or more sulfur atoms. Many of these compounds function as CHOLINERGIC AGENTS and as INSECTICIDES. Compounds, Organothiophosphorus
D011833 Radiation Injuries, Experimental Experimentally produced harmful effects of ionizing or non-ionizing RADIATION in CHORDATA animals. Experimental Radiation Injuries,Injuries, Experimental Radiation,Experimental Radiation Injury,Radiation Injury, Experimental
D011837 Radiation-Protective Agents Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military. Radiation Protectant,Radiation Protective Agent,Radiation-Protective Agent,Radiation-Protective Drug,Radioprotective Agent,Radioprotective Agents,Radioprotective Drug,Agents, Radiation-Protective,Radiation Protectants,Radiation Protective Agents,Radiation-Protective Drugs,Radiation-Protective Effect,Radiation-Protective Effects,Radioprotective Drugs,Agent, Radiation Protective,Agent, Radiation-Protective,Agent, Radioprotective,Agents, Radiation Protective,Agents, Radioprotective,Drug, Radiation-Protective,Drug, Radioprotective,Drugs, Radiation-Protective,Drugs, Radioprotective,Effect, Radiation-Protective,Effects, Radiation-Protective,Protectant, Radiation,Protectants, Radiation,Protective Agent, Radiation,Protective Agents, Radiation,Radiation Protective Drug,Radiation Protective Drugs,Radiation Protective Effect,Radiation Protective Effects
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004999 Amifostine A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. Ethiofos,Gammaphos,APAETP,Amifostine Anhydrous,Amifostine Disodium Salt,Amifostine Monohydrate,Amifostine Monohydrochloride,Amifostine Trihydrate,Aminopropyl Aminoethylthiophosphate,Aminopropylaminoethylthiophosphate,Aminopropylaminoethylthiophosphoric Acid,Ethanethiol, 2-((3-aminopropyl)amino)-, dihydrogen phosphate (ester), trihydrate,Ethiofos Anhydrous,Ethyol,NSC-296961,S-(N-(3-Aminopropyl)-2-aminoethyl)thiophosphoric Acid,WR-2721,YM-08310,NSC 296961,NSC296961,WR 2721,WR2721,YM 08310,YM08310
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014018 Tissue Distribution Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios. Distribution, Tissue,Distributions, Tissue,Tissue Distributions

Related Publications

V G Vladimirov, and I P Kamenko, and G A Poddubskiĭ, and S M Smirnova, and L G Tarnopol'skaia
September 1988, Meditsinskaia radiologiia,
V G Vladimirov, and I P Kamenko, and G A Poddubskiĭ, and S M Smirnova, and L G Tarnopol'skaia
January 1990, Radiobiologiia,
V G Vladimirov, and I P Kamenko, and G A Poddubskiĭ, and S M Smirnova, and L G Tarnopol'skaia
January 1977, Radiobiologiia,
V G Vladimirov, and I P Kamenko, and G A Poddubskiĭ, and S M Smirnova, and L G Tarnopol'skaia
January 1973, Farmakologiia i toksikologiia,
V G Vladimirov, and I P Kamenko, and G A Poddubskiĭ, and S M Smirnova, and L G Tarnopol'skaia
January 1973, Radiobiologiia,
V G Vladimirov, and I P Kamenko, and G A Poddubskiĭ, and S M Smirnova, and L G Tarnopol'skaia
January 1984, Radiobiologiia,
V G Vladimirov, and I P Kamenko, and G A Poddubskiĭ, and S M Smirnova, and L G Tarnopol'skaia
January 1968, Farmakologiia i toksikologiia,
V G Vladimirov, and I P Kamenko, and G A Poddubskiĭ, and S M Smirnova, and L G Tarnopol'skaia
January 1970, Radiobiologiia,
V G Vladimirov, and I P Kamenko, and G A Poddubskiĭ, and S M Smirnova, and L G Tarnopol'skaia
January 1990, Radiobiologiia,
V G Vladimirov, and I P Kamenko, and G A Poddubskiĭ, and S M Smirnova, and L G Tarnopol'skaia
January 1986, Radiobiologiia,
Copied contents to your clipboard!